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Botulinum Toxin Injection and Airflow Stability in
Spasmodic Dysphonia
Giovanna Cantarella, MD, Alessandra Berlusconi, MD,
Barbara Maraschi, BSc, Alain Ghio, PhD, and Sergio Barbieri, MD,
Milan, ItalyOBJECTIVE: The aim of this study was to analyze the effects of
botulinum toxin (BT) injection on airflow stability, by measuring
mean phonatory oral airflow and its coefficient of variation (CV),
in subjects with adductor spasmodic dysphonia (SD).
STUDY DESIGN AND SETTING: Twenty-four subjects with
SD (aged 31-78 years) and 23 controls (aged 29-63 years) were
evaluated for mean airflow and its CV during sustained phonation.
Fifteen of the subjects with SD were also evaluated within 3 weeks
after BT injection.
RESULTS: BT increased airflow in subjects (P  0.0130) but
neither the preinjection nor postinjection values differed signifi-
cantly from those of controls. Conversely, airflow CV was invari-
ably higher in subjects than in controls (P  0.0001). In 13
subjects in whom phonation perceptually improved, including 3 in
whom airflow did not increase, airflow CV decreased significantly
after BT treatment (P  0.0232).
CONCLUSIONS: Subjects with SD have highly unstable pho-
natory airflow; its CV is a valid measure for assessing the out-
come of a BT injection. A reduced airflow CV probably does not
depend solely on increased airflow due to thyroarytenoid muscle
paresis, and may indicate a change in laryngeal motoneuronal
activity.
EBM rating: B-3b
© 2006 American Academy of Otolaryngology–Head and Neck
Surgery Foundation, Inc. All rights reserved.
Spasmodic dysphonia (SD) is a disabling motor disorderaffecting the voice. Whereas in the past it was diagnosed
and treated as a psychiatric disorder, it is currently consid-
ered to be a focal dystonia affecting the intrinsic laryngeal
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abductor, mixed SD and SD with tremor.1-4 Although sub-
jects with SD have a typically strained and strangled voice
the grade of voice impairment varies greatly depending on
the muscles involved by spasms, the severity of muscle
hyperactivity, and the compensatory mechanisms during
speech. The resulting speech characteristics are therefore
influenced by several mechanisms and SD is described as a
heterogeneous disorder.3,5
Whether SD is a single disease or it may arise from
various pathophysiologic conditions is unclear. Previous
investigations have shown that botulinum toxin (BT) injec-
tion into the thyroarytenoid (TA) muscles is the most effec-
tive symptomatic treatment for adductor SD,6 as it is for
other types of focal dystonia. BT acts peripherally by in-
hibiting acetylcholine (Ach) release from the presynaptic
nerve terminals thereby causing a flaccid paralysis of the
injected muscle.
Only a few studies have analyzed the aerodynamic fea-
tures of phonation in subjects with SD and described
changes after BT treatment of the vocal muscles.7-11 Al-
though subjects with SD would be expected to have a low
translaryngeal airflow owing to overclosure of the vocal
folds,9,10,12 some investigators report mean airflow within
normal limits.7,13
Because BT acts by paralyzing the TA muscles, BT
injections usually increase airflow.7-11 A limited number of
studies have analyzed the variations in airflow during pho-
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SD and assessing changes induced by BT treatment.7,8,12
In this study we investigated whether aerodynamic eval-
uation of voice production is useful in the diagnostic as-
sessment and follow-up of subjects with SD undergoing BT
treatment. To evaluate airflow stability over time, we mea-
sured mean oral airflow and its coefficient of variation (CV)
during sustained phonation in subjects with adductor SD
and in a group of control subjects and analyzed changes in
both aerodynamic measures in subjects after BT treatment.
MATERIAL AND METHODS
Subjects
We studied 24 subjects (19 women, 5 men; aged 31-78
years, mean age  54.7) with adductor SD. Severity ranged
from mild impairment of fluency to unintelligible speech in
the most severe cases. The diagnosis was made by a neu-
rolaryngological team comprising a laryngologist, a speech
therapist and a neurologist, and mainly based on the pres-
ence of a strained, strangled quality of voice with phonatory
breaks and on the subject’s clinical history. Flexible video
laryngoscopy confirmed over adduction and spasms of the
vocal folds coinciding with the voice stops.
As a control group we enrolled 23 normal subjects (13
women, 10 men; aged 29-63 years, mean age  53.4) with
no history of voice disorders. The protocol was approved by
the hospital ethics committee and all participants gave their
informed consent to the study.
Botulinum Toxin Treatment
All of the subjects received a percutaneous injection of BT
type A (Botox) in both TA muscles under electromyographic
guidance. Of the 24 subjects treated, 18 were receiving their
first BT treatment, and 6 were being retreated. Botulinum toxin
was injected at a dose of 2.5 mouse units per side in 15 subjects
and the dose ranged from 0.675 to 5 U per side in the remain-
ing 9 subjects, depending on the severity of symptoms or the
previous response to treatment, or both. Botulinum toxin was
injected at a concentration of 2.5 U/0.1 ml (1.25 U/0.1 ml in
subjects receiving 2.5 U per TA muscle).
Aerodynamic Recordings
The mean airflow was recorded while subjects and controls
produced a sustained /a/ at comfortable pitch and intensity
for at least 3 sec, and was measured with EVA2 workstation
(SQ-Lab, Aix-en-Provence, France). A mouthpiece was
placed on the subject’s face, and held tightly around the
mouth, to avoid air leaks. The mouthpiece was equipped
with built-in acoustic and aerodynamic sensors that were
coaxially arranged, to allow simultaneous recordings of
acoustic and aerodynamic variables.
Airflow was measured with a constant-temperature mesh
pneumotachograph. Voice data were displayed on the com-
puter screen as four superposed curves corresponding to thesound wave, fundamental frequency in Hz, sound pressure
level (SPL) intensity in dB, and airflow in dm3/sec. A 1-sec
segment was then selected for analysis in the steadiest part
of the tracings. The EVA2 software was used to compute
the acoustic and aerodynamic data. Acoustic results are not
considered in this paper. Airflow values were measured in
dm3/sec and converted to cc/sec.
The CV of airflow, expressed as a percentage, was cal-
culated by dividing the SD of airflow by the mean airflow:
CV 100
airflow sd
mean airflow
The CV therefore expresses the middle term instability of
airflow and can be seen as the scope in % of airflow around
its average value. Aerodynamic indexes were assessed be-
fore treatment in all subjects and in 15 subjects the record-
ing was repeated within 3 weeks (range  8-20 days, mean
 14.4) after treatment, when the voice improvement had
stabilized and breathiness had subsided.
Statistical Analysis
All analyses were carried out using the GraphPad Prism
statistical program. All values are expressed as means 
standard deviation (SD). The Mann-Whitney test for inde-
pendent variables was used to compare the mean airflow
and the CV values in subjects and control subjects. Stu-
dent’s t-test for paired data was used to compare mean
airflow and CV values before and after BT treatment in the
13 subjects achieving voice improvement. A P value of
0.05 was considered statistically significant.
RESULTS
Aerodynamic Results in Subjects With SD
Versus Normal Subjects
No significant difference was found in mean preinjection
airflow values recorded in the 24 subjects and 23 controls (P
 0.0928) (Fig 1). In both groups mean airflow showed a
high degree of variability although 4 subjects (only 1 con-
trol) had airflow values below 50 cc/sec. Two subjects
exhibited values over 300 cc/sec (383 and 671 cc/sec). The
airflow values ranged from 24 to 671 cc/sec in the SD
subjects (mean 145.2 138.0 cc/sec) and from 46 to 259
cc/sec in the controls (mean  156.0  57.5 cc/sec). Con-
versely, mean CV of airflow values were significantly
higher in subjects than in controls (P  0.0001): 64.8 
88.3% (range  5.4% to 329.1%) vs 3.7  2.1% (range 
1.2% to 8.0%) (Fig 2).
Aerodynamic Evaluation After BT Treatment
Aerodynamic recordings were repeated within 3 weeks after
treatment in 15 of 24 subjects receiving BT injection in the
TA muscles. The remaining 9 subjects were followed up
only by telephone because they lived far away from our
laboratory. Only 13 of 15 subjects who underwent post BT
421Cantarella et al Botulinum Toxin Injection and Airflow Stability in . . .treatment recordings had a subjective and acoustic improve-
ment in voice quality and fluency. In the 2 unimproved
subjects postinjection airflow and CV of airflow values were
similar to those obtained before treatment.
In the 13 subjects who benefitted from BT treatment,
mean preinjection and postinjection airflow values differed
significantly (P  0.0130), the mean preinjection value
being 106.5 61.9 cc/sec (range 26-205 cc/sec) vs 237.2
 138.8 cc/sec (range  78-581 cc/s) (Fig 3). In 10 of 13
subjects airflow increased, it remained unchanged in 2, and
in the remaining female subject it significantly diminished
(preinjection 182 cc/sec vs postinjection 78 cc/sec). The
difference between postinjection airflow values in subjects
and controls was borderline but did not reach significance
(P  0.0652).
In 12 of 13 subjects in whom BT treatment improved
phonation, including 1 subject in whom airflow also de-
Figure 1 Values of phonatory oral airflow in the 24 subjects
with adductor spasmodic dysphonia and 23 normal subjects. Note
the wide dispersion of data in both groups. No significant differ-
ence was found between the 2 groups.
Figure 2 Coefficients of variation of airflow in subjects with
spasmodic dysphonia and controls. Subjects values are signifi-
cantly higher than those of controls.creased, the mean CV of airflow diminished (preinjection:
48.9  52.8%, range  12.7% to 213.5% vs postinjection:
9.9  7.5%, range  1.6% to 27.7%). The decrease was
statistically significant (P  0.0232) (Fig 4). The CV values
were still significantly higher in treated subjects than in
controls (P  0.0006). In the subject in whom airflow
decreased after BT treatment, CV diminished from 33.7% to
13.2%.
Figure 5 reports an example of preinjection and postin-
jection airflow tracings in one of the subjects whose voice
improved significantly. In this particular case a very high
stability of airflow (demonstrated by a significant reduction
of CV) was achieved after treatment without a significant
quantitative change in airflow.
RESULTS
The results reported in this study confirm the usefulness of
aerodynamic evaluation of phonation in the diagnostic
Figure 3 Graph showing pre- and post-BT treatment mean oral
airflow (airflow) measured in 13 subjects with spasmodic dyspho-
nia and in the 23 controls. Although post-treatment values are
significantly higher than the pre-treatment values, they do not
significantly differ from those of controls.
Figure 4 After BT treatment the coefficients of variation of oral
airflow are significantly reduced, but they are still significantly
higher than those of controls.
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disorder, undergoing treatment with BT.
A few previous studies have measured oral airflow9-11
and its variability7,8,12 in SD subjects; the results were
inconsistent. A low airflow in SD is an expected find-
ing9,10,12 considering the pathophysiology of the disease,
because the over adduction of vocal folds during phonation
may well hinder the normal flow of air through the glottis.
Nevertheless some authors have reported mean airflow
within normal limits.7,13 The subjects we studied, all of
whom had adductor SD, had airflow values ranging from 24
to 671cc/sec, reflecting the heterogeneity of SD (Fig 1).
Airflow values ranged widely also in the control group,
confirming previous findings in normal subjects.14 Subjects
had lower airflow values than healthy controls although the
difference was not significant (P 0.0928), probably owing
to data dispersion.
Besides reflecting the widely ranging severity of disease,
airflow may differ also owing to the various pathophysiologi-
cal mechanisms. The several different types and subtypes of
SD vary depending on the muscles involved by dystonic ac-
tivity and also on other associated neurologic signs and symp-
toms. A recent study15 shows that all the intrinsic laryngeal
muscles can be involved by dystonic activity in SD. Further-
more, the clinical presentation of adductor SD, the most com-
mon laryngeal dystonia, may differ if the disorder is associated
with glottic tremor or if the subject uses compensatory mech-
anisms to avoid voice breaks. Some subjects with adductor SD
Figure 5 Tracings obtained before (A) and 18 days after (B)
botulinum-A treatment in a 31-year-old female subject. The upper
tracings are the sound waveforms whereas the lower tracings
display the oral airflow (airflow) during the emission of a sustained
vowel /a/. Waveforms and airflow tracings are both much more
stable in the post-treatment recording. Despite similar airflow
values (167 cc/sec pre- and 164 cc/sec post-treatment), the airflow
coefficient of variation has reduced from 12.71% to 2.06%.adopt a whispered voice to overcome laryngeal spasms and tobe able to communicate; this could explain why 2 subjects in
our series had very high airflow values (383 and 671 cc/sec).
Unfortunately neither of these 2 subjects was available for a
postinjection recording. Owing to its broad range of values,
airflow therefore seems unreliable as a diagnostic test but may
be useful for tracking functional changes during follow-up.
After BT treatment mean airflow increased in 10 of 13
subjects (of the 15 available post-treatment recordings),
who experienced a subjective and perceptual voice im-
provement (Fig 3). The mean postinjection flow value was
higher in subjects than in normal subjects, but the difference
was not statistically significant.
Our results provide further evidence that the high CV of
airflow in subjects with SD reflects the dystonic activity in
the TA muscles during phonation. The subjects we studied
had remarkably higher CV values than controls before treat-
ment (Fig 2) and values decreased significantly after BT
treatment (Fig 4). These results confirm previous findings
by others,7,8,11 although our range is wider (5.4% to 329.1%
compared to 21.5% to 141%, Davis et al,12 and 16.5% to
146.4%, Finnegan et al7). The various series are difficult to
compare also because they consider different voice samples.
Whereas we used a sustained /a/, others7,8 analyzed the
vowel /i/ in a syllable repetition task and on a shorter
segment of voice production.
Although the absolute value of airflow will not discriminate
subjects with SD from normal subjects, the CV of airflow
allowed such a discrimination. Even after BT treatment most
of our subjects still had significantly higher CV values than
controls (Fig 4). Hence, even though the stability of the glottic
vibrator improved, it did not return to normal.
In most subjects (12 of 13) in whom BT treatment
improved phonation the reduced postinjection CV showed
that airflow stability increased remarkably. Yet in 2 of 12
subjects airflow remained unchanged and in 1 of 12 it
decreased. The tracings obtained in 1 of 3 subjects who had
no increase in airflow after BT treatment (Fig 5) clearly
show that despite having normal preinjection and postinjec-
tion airflow values (167 cc/sec and (164 cc/sec), she had a
markedly reduced CV (from 12.7% to 2.06%). This subject
achieved an excellent voice quality. Only one subject
showed a marked reduction in airflow after treatment (see
Results), although unexpectedly the CV also decreased re-
markably. These findings seem to indicate that the higher
steadiness of airflow is not entirely due to the flaccid paresis
of the TA muscles obtained through BT peripheral action at
the neuromuscular junction. Conversely, they imply that the
improved stability of the laryngeal muscular system might
arise from a central action of BT. Hence our findings could
be in line with the conclusion of Finnegan et al7 that “in-
creased stability of airflow could reflect [. . .] an increase in
stability of the neural signal from the laryngeal motor neu-
ron pool.”
Although BT-A decreases muscle hyperactivity in dys-
tonic muscles by preventing Ach release at the neuromus-
cular junction, some evidence suggests central nervous sys-
423Cantarella et al Botulinum Toxin Injection and Airflow Stability in . . .tem (CNS) effects.7,16,17 When injected into a muscle, BT-A
could affect the CNS either by a direct action, through
retrograde axonal transport to the central structures, or in-
directly, by altering the sensory inputs to the CNS, through
a peripheral effect.16,17 An experimental study18 has shown
that BT injected into the cat gastrocnemius muscle is trans-
ported to the spinal cord segments innervating the injected
muscle. This study supports the hypothesis that BT may
influence spinal cord circuitry through motor and intrafusal
afferent axons. Furthermore, when injected into a muscle,
BT causes denervation of both the intrafusal and extrafusal
fibers.19 As a consequence, the spindle afferent input could
be reduced or altered and ultimately this change might
influence the central feedback mechanisms that modulate
the activity of laryngeal muscles. Muscles spindles have
been described in the intrinsic laryngeal muscles,20 and
other mechanoreceptors in laryngeal joints.21 The sensory
feedback deriving from muscles spindles and from the other
mechanoreceptors probably influences the activity of the
entire laryngeal motoneuron pool. This hypothesis receives
support from clinical studies evaluating the effects of
unilateral BT injection on the contralateral laryngeal mus-
cles.10,16 After injecting BT-A into the TA muscle unilat-
erally, Bielamowicz and Ludlow16 found that electromyo-
graphic activity from both TA and cricothyroid muscles was
reduced; they postulated that the achieved voice improve-
ment could be due to both the well-known peripheral and to
a central action of BT. Videoendoscopic observations by
Zwirner et al10 showed that unilateral BT treatment reduced
the dystonic contraction in laryngeal intrinsic muscles bi-
laterally.
CONCLUSIONS
In our study we treated TA muscles bilaterally. In three
subjects stability of airflow persisted even when breathiness
had subsided and airflow returned to a value similar or even
lower than the preinjection one. Why it did so is unclear. SD
is a complex disturbance of phonation that probably in-
volves at the same time several laryngeal muscles,2 any of
which may be predominant.15 In their study, Cannito and
Johnson2 defined SD as a “continuum disorder” meaning
that adductor and abductor spasms may both occur with
different frequencies in the same subject. We hypothesize
that BT injection into TA muscles might also modify the
dystonic activity in other laryngeal muscles involved by
spasms, either by diffusion or through an indirect effect, by
reducing sensory inputs to the CNS.
As a further development of the study, serial recordings
of airflow and CV, between consecutive treatments, could
be helpful to evaluate whether changes in the two variables
are related. Our data confirm the validity of aerodynamic
measures in studying the pathophysiology of spasmodic
dysphonia and in monitoring voice changes after BT treat-
ment. Studies of airflow stability may help to explain the
possible effects of botulinum toxin on the CNS.REFERENCES
1. Aronson AE, Brown JR, Litin EM, et al. Spastic dysphonia, II. Com-
parison with essential (voice) tremor and other neurologic dysphonias.
J Speech Hearing Disord 1968;33:219–31. (Grade C).
2. Cannito MP, Johnson JP. Spastic dysphonia: a continuum disorder.
J Commun Disord 1981;14:215–23. (Grade C).
3. Aronson AE. Clinical voice disorders. 2nd ed. New York: Thieme,
1985. (Grade D).
4. Blitzer A, Brin MF, Fahn S, et al. Clinical and laboratory character-
istics of laryngeal dystonia: a study of 110 cases. Laryngoscope 1988;
98:636–40. (Grade C).
5. Pool KD, Freeman FJ, Finitzo T, et al. Heterogeneity in spasmodic
dysphonia. Neurologic and voice findings. Arch Neurol
1991;48:305–9. (Grade C).
6. Blitzer A, Brin FB, Stewart CF. Botulinum toxin management of
spasmodic dysphonia (laryngeal dystonia): a 12-year experience in
more than 900 patients. Laryngoscope 1998;108:1435–41. (Grade C).
7. Finnegan E, Luschei E, Gordon J, et al. Increased stability of airflow
following botulinum toxin injection. Laryngoscope 1999;109:1300–6.
(Grade B).
8. Adams S, Durkin L, Irish J, et al. Effects of botulinum toxin type A
injection on aerodynamic measures of spasmodic dysphonia. Laryn-
goscope 1996;106:296–300. (Grade B).
9. Woo P, Colton R, Casper J, et al. Analysis of spasmodic dysphonia by
aerodynamic and laryngostroboscopic measurements. J Voice 1992;6:
344-51. (Grade C).
10. Zwirner P, Murry T, Swenson M, et al. Effects of botulinum toxin
therapy in patients with adductor spasmodic dysphonia: acoustic, aero-
dynamic, and videoendoscopic findings. Laryngoscope 1992;102:
400–6. (Grade C).
11. Metha RP, Goldman SN, Orloff LA. Long-term therapy for spasmodic
dysphonia: acoustic and aerodynamic outcomes. Arch Otolaryngol
Head Neck Surg 2001;127:393–9. (Grade B).
12. Davis PJ, Boone DR, Carroll RL, et al. Adductor spastic dysphonia:
heterogeneity of physiologic and phonatory characteristics. Ann Otol
Rhinol Laryngol 1988;97:179–85. (Grade C).
13. Hirano M, Koike Y, von Leden H. Maximum phonation time and air
usage during phonation. Folia Phoniatri (Basel) 1968;20:185–201.
(Grade C).
14. Schutte HK. Aerodynamics of phonation. Acta Otorhinolaryngol Belg
1986;40:344–57. (Grade B).
15. Klotz DA, Maronian NC, Waugh PF, et al. Findings of multiple
muscle involvement in a study of 214 patients with laryngeal dystonia
using fine-wire electromyography. Ann Otol Rhinol Laryngol 2004;
113:602–12. (Grade C).
16. Bielamowicz S, Ludlow CL Effects of botulinum toxin on pathophys-
iology in spasmodic dysphonia. Ann Otol Rhinol Laryngol 2000;109:
194–203. (Grade C).
17. Currà A, Trompetto C, Abbruzzese G, et al. Central effects of botu-
linum toxin type A: evidence and supposition. Mov Disord 2004;
19(Suppl):S60–4. (Grade D).
18. Wiegand H, Herman G, Woohoner HH. 125I-labelled botulinum A
neurotoxin: pharmacokinetics in cats after intramuscular injection.
Naunyn Schmiedebergs Arch Pharmacol 1976;292:161–5. (Grade C).
19. Rosales RL, Arimura K, Takenaga S, et al. Extrafusal and intrafusal
muscle effects in experimental botulinum toxin-A injection. Muscle
Nerve 1996;19:488–96. (Grade C).
20. Lucas Keene MF. Muscle spindles in the human laryngeal muscles. J
Anat 1961;95:25–9. (Grade C).
21. Suzuki M, Kirchner JA. Sensory fibers in the recurrent laryngeal
nerve. An electrophysiological study of some laryngeal afferent fibers
in the recurrent laryngeal nerve of the cat. Ann Otol Rhinol Laryngol
1969;78:21–31. (Grade C).
